CA2169173A1 - Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques - Google Patents

Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques

Info

Publication number
CA2169173A1
CA2169173A1 CA002169173A CA2169173A CA2169173A1 CA 2169173 A1 CA2169173 A1 CA 2169173A1 CA 002169173 A CA002169173 A CA 002169173A CA 2169173 A CA2169173 A CA 2169173A CA 2169173 A1 CA2169173 A1 CA 2169173A1
Authority
CA
Canada
Prior art keywords
methods
thrombopoietin
stimulating erythropoiesis
erythropoiesis
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002169173A
Other languages
English (en)
Other versions
CA2169173C (fr
Inventor
Kenneth Kaushansky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
Kenneth Kaushansky
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Kaushansky, University Of Washington filed Critical Kenneth Kaushansky
Publication of CA2169173A1 publication Critical patent/CA2169173A1/fr
Application granted granted Critical
Publication of CA2169173C publication Critical patent/CA2169173C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
CA002169173A 1994-02-14 1995-02-09 Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques Expired - Fee Related CA2169173C (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US19602594A 1994-02-14 1994-02-14
US08/196,025 1994-02-14
US20319794A 1994-02-25 1994-02-25
US08/203,197 1994-02-25
US21520394A 1994-03-21 1994-03-21
US08/215,203 1994-03-21
US25249194A 1994-06-01 1994-06-01
US08/252,491 1994-06-01
US28841794A 1994-08-09 1994-08-09
US08/288,417 1994-08-09
US33556694A 1994-11-07 1994-11-07
US08/335,566 1994-11-07
US34774894A 1994-12-01 1994-12-01
US08/347,748 1994-12-01
PCT/US1995/001829 WO1995021626A1 (fr) 1994-02-14 1995-02-09 Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques

Publications (2)

Publication Number Publication Date
CA2169173A1 true CA2169173A1 (fr) 1995-08-17
CA2169173C CA2169173C (fr) 2002-10-15

Family

ID=27569260

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002169173A Expired - Fee Related CA2169173C (fr) 1994-02-14 1995-02-09 Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques

Country Status (6)

Country Link
EP (1) EP0723456A1 (fr)
AU (1) AU1843595A (fr)
CA (1) CA2169173C (fr)
FI (1) FI960930A0 (fr)
NZ (1) NZ281482A (fr)
WO (1) WO1995021626A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6316254B1 (en) * 1994-02-14 2001-11-13 University Of Washington Methods for stimulating erythropoiesis using hematopoietic proteins
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
RO115788B1 (ro) * 1994-03-31 2000-06-30 Amgen Inc. Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP1961760A3 (fr) 1995-06-07 2008-09-03 Glaxo Group Limited Peptides et composés se liant à un récepteur de la thrombopoïétine
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
PT1542714E (pt) 2002-09-18 2014-06-23 Janssen Pharmaceuticals Inc Métodos para aumentar a produção de células estaminais plaquetárias e hematopoiéticas
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
PL1675606T3 (pl) 2003-08-28 2017-08-31 Janssen Pharmaceuticals, Inc. Peptydy i związki, które wiążą się z receptorami trombopoetyny
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
DK1984014T3 (da) * 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi

Also Published As

Publication number Publication date
FI960930A (fi) 1996-02-28
NZ281482A (en) 2000-09-29
AU1843595A (en) 1995-08-29
EP0723456A1 (fr) 1996-07-31
WO1995021626A1 (fr) 1995-08-17
CA2169173C (fr) 2002-10-15
FI960930A0 (fi) 1996-02-28

Similar Documents

Publication Publication Date Title
CA2169173A1 (fr) Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques
GEP20022804B (en) Erythropoietin Derivatives
AU6780687A (en) Benzamido-aromatic derivatives, process for their preparation and their use in human or veterinary medicine and in cosmetics
DE69718053T2 (de) in vitro methoden und verwendung von pharmazeutische zusammensetzungen für die BEHANDLUNG VON INNENOHRHAARZELLEN
CA2276180A1 (fr) Procede d'activation de cellules presentatrices d'antigene humain, cellules presentatrices d'antigene humain activees et utilisation desdites cellules
CZ200151A3 (en) Sulfur-substituted N-arylamides of sulfonylaminocarboxylic acid, process of their preparation, their use and pharmaceutical preparations in which they are comprised
MX9603927A (es) Metodo para la estimulacion de hematopoyesis con hemoglobina.
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
WO1996015758A3 (fr) Procedes de stimulation de l'erythropoiese a l'aide de la trombopoietine
AU586920B2 (en) Aromatic compounds process for their preparation, and their use in human and veterinary medicine and in cosmetics
HUP0301030A3 (en) New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
HU9802577D0 (en) In vivo dyeing material, process for producing thereof and use for identifying of living tissues
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
CA2094275A1 (fr) Methodes et compositions pour le traitement de maladies cytoproliferatives
ITRM970238A0 (it) Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella terapia di patologie corneali e congiuntivali
CA2319542A1 (fr) Traitement des troubles de la sexualite chez certains groupes de patients
EP0821969A3 (fr) Composition médicale contenant du TCF-II
AU7926487A (en) Apparatus for effect-field treatment matched with the human body's frequency spectrum and their production method
AU3255295A (en) Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
CA2305764A1 (fr) Sels d'acides biliaires de metaux comportant une action physiologique, et utilisation de ceux-ci en therapie
IL97801A0 (en) Oligonucleotides,methods for in vitro tissue cell culture using the same and cosmetic compositions containing the same
EP0668771A4 (fr) Traitement des maladies autoimmunes par induction d'une tolerance des cellules, des tissus et des organes.
AU5448490A (en) Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
UA23999C2 (uk) Спосіб одержаhhя засобу "біпекс" для лікуваhhя hейрооhкологічhих захворюваhь

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed